This continues a consistent rise in pay for the specialty—the same report recorded cardiology’s average salary as $459,000 in 2021, $438,000 in 2020 and $430,000 in 2019.

“If you were a patient of Dr. Verga’s, your heart was in brilliant hands,” according to one loving tribute. The 45-year-old cardiologist had been missing since March 20. 

Did SAVR outcomes suffer due to the rapid rise of TAVR? A team of researchers aimed to find out with a brand new analysis. 

Several late-breaking clinical trials at ACC.22 will likely impact clinical practice. Below are summaries of a few key trials and their takeaways for interventional cardiology and structural heart interventions. 

The recall is focused on a single batch distributed from December 2021 to March 2022.

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

The study's authors examined data from the DANAMI-3 trial, focusing on such outcomes as all-cause mortality, recurrent MI and target vessel revascularization.

An international analysis published in Circulation and a new scientific statement from the American Heart Association both explore the latest data on heart complications associated with COVID-19. 

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

Self-expanding heart valves and the presence of significant PVL were both linked to a heightened risk of mitral valve infective endocarditis after TAVR.